Safety Study of Albuterol Spiromax® in Subjects With Asthma
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks
during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period
followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax®
device performance through the life of the device during the study.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries